Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models. [electronic resource]
Producer: 20200617Description: 1931-1944 p. digitalISSN:- 1557-3125
- Administration, Oral
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Benzoxazoles -- administration & dosage
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Cell Survival -- drug effects
- Dose-Response Relationship, Drug
- Drug Synergism
- Humans
- Imidazoles -- administration & dosage
- Male
- Mechanistic Target of Rapamycin Complex 1 -- antagonists & inhibitors
- Mechanistic Target of Rapamycin Complex 2 -- antagonists & inhibitors
- Mice
- Morpholines -- administration & dosage
- Paclitaxel -- administration & dosage
- Pyridines -- administration & dosage
- Pyrimidines -- administration & dosage
- Urinary Bladder Neoplasms -- drug therapy
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.